利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.024 秒)

    Detection of nucleic acid hybrids by prolonged chemiluminescence
    1.
    发明授权
    Detection of nucleic acid hybrids by prolonged chemiluminescence 失效
    通过延长化学发光检测核酸杂交体

    公开(公告)号：US4794073A

    公开(公告)日：1988-12-27

    申请号：US753734

    申请日：1985-07-10

    申请人： Nanibhushan Dattagupta ,  Anton H. Clemens

    发明人： Nanibhushan Dattagupta ,  Anton H. Clemens

    IPC分类号： C12Q1/28 ,  C12Q1/68 ,  G01N33/533 ,  C07H21/00

    CPC分类号： G01N33/533 ,  C12Q1/28 ,  C12Q1/6816

    摘要： A nucleic acid probe capable of participating in a chemiluminescent reaction comprising a defined nucleic acid sequence, the sequence being linked to any one ofa. a chemiluminescence precursor,b. a chemiluminescence enhancer, andc. an enzyme the remaining two of (a), (b) and (c) not linked to the sequence being in a mixture of the linked sequence. A method for determining a particular single stranded polynucleotide sequence in a test medium, comprising the steps of:(a) combining the test medium with a polynucleotide probe having a base sequence substantially complementary to the sequence to be determined,(b) labeling either the resulting hybrids or probe which has not hybridized with the sequence to be determined with one of the participants in an enhanced chamiluminescent reaction involving a chemiluminescent precursor, an enzyme, an oxidant, and a chemiluminescence enhancer,(c) initiating such chemiluminent reaction with the labeled hybrid or probe, and(d) detecting the resulting light emission.

    摘要翻译： 能够参与化学发光反应的核酸探针，其包含限定的核酸序列，所述序列与a的任一个连接。 化学发光前体，b。 化学发光增强剂，和c。 （a），（b）和（c）的剩余两个与连接序列的混合物中的序列没有连接的酶。 一种用于在测试培养基中测定特定单链多核苷酸序列的方法，包括以下步骤：（a）将测试培养基与具有与待测序列基本上互补的碱基序列的多核苷酸探针合并，（b） 所产生的杂交体或探针，其未与与参与者之一的待测序列杂交，所述参与者涉及化学发光前体，酶，氧化剂和化学发光增强剂的增强的倒立发光反应，（c）开始与标记的化学发光反应 杂交或探针，和（d）检测所得到的光发射。

    Method of restoring the incretin effect
    2.
    发明授权
    Method of restoring the incretin effect 有权
    恢复肠降血糖素作用的方法

    公开(公告)号：US08445508B2

    公开(公告)日：2013-05-21

    申请号：US12906735

    申请日：2010-10-18

    申请人： Anton H. Clemens

    发明人： Anton H. Clemens

    IPC分类号： A61K31/44 ,  A61K31/215 ,  A61K31/195

    CPC分类号： A61K31/485 ,  A61K31/437 ,  A61K31/4748 ,  A61K38/45 ,  A61K45/06 ,  Y10S514/866

    摘要： The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective κ-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof.

    摘要翻译： 本发明涉及治疗代谢综合征，2型糖尿病，致动脉粥样化血脂异常和/或肥胖症的方法。 本发明还涉及恢复肠降血糖素作用，恢复胰高血糖素水平的生理控制，恢复第一阶段胰岛素分泌和恢复生理葡萄糖依赖性胰岛素分泌的方法。 本发明的方法包括向有需要的受试者施用选择性κ-受体拮抗剂，例如胍基化的纳曲酮（GNTI）或其药学上可接受的衍生物。

    Method of treating hyperlipidemia in humans
    3.
    发明授权
    Method of treating hyperlipidemia in humans 失效
    治疗人类高脂血症的方法

    公开(公告)号：US5727570A

    公开(公告)日：1998-03-17

    申请号：US749333

    申请日：1996-11-14

    申请人： Anton H. Clemens

    发明人： Anton H. Clemens

    IPC分类号： A61K31/198 ,  A61K31/485 ,  A61B19/00

    CPC分类号： A61K31/198 ,  A61K31/485

    摘要： A method of treatment of humans suffering from hyperlipidemia which comprises administering, by a pharmaceutically effective mode, a drug composition selected from the group consisting of opiate antagonists, and drugs which substantially equally reduce the amounts of catecholamines bound to all catecholamine binding sites, is disclosed.

    摘要翻译： 公开了一种治疗患有高脂血症的人的方法，其包括以药学上有效的方式施用选自阿片剂拮抗剂的药物组合物和与所有儿茶酚胺结合位点结合的儿茶酚胺基本相同的量的药物 。

    METHOD OF RESTORING THE INCRETIN EFFECT
    4.
    发明申请
    METHOD OF RESTORING THE INCRETIN EFFECT 有权
    恢复增强效应的方法

    公开(公告)号：US20110118293A1

    公开(公告)日：2011-05-19

    申请号：US12906740

    申请日：2010-10-18

    申请人： Anton H. Clemens

    发明人： Anton H. Clemens

    IPC分类号： A61K31/485 ,  A61P3/04

    CPC分类号： A61K31/485 ,  A61K31/437 ,  A61K31/4748 ,  A61K38/45 ,  A61K45/06 ,  Y10S514/866

    摘要： The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective κ-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof.

    摘要翻译： 本发明涉及治疗代谢综合征，2型糖尿病，致动脉粥样化血脂异常和/或肥胖症的方法。 本发明还涉及恢复肠降血糖素作用，恢复胰高血糖素水平的生理控制，恢复第一阶段胰岛素分泌和恢复生理葡萄糖依赖性胰岛素分泌的方法。 本发明的方法包括向有需要的受试者施用选择性和受体拮抗剂，例如胍基化的纳曲酮（GNTI）或其药学上可接受的衍生物。

    Catheter sharp retraction system
    5.
    发明授权
    Catheter sharp retraction system 失效
    导管尖锐缩回系统

    公开(公告)号：US5376075A

    公开(公告)日：1994-12-27

    申请号：US114473

    申请日：1993-08-31

    申请人： Victor M. Haughton ,  Anton H. Clemens

    发明人： Victor M. Haughton ,  Anton H. Clemens

    IPC分类号： A61M25/00 ,  A61M5/158 ,  A61M5/32 ,  A61M25/06 ,  A61M5/00

    CPC分类号： A61M25/0637 ,  A61M25/0631 ,  A61M5/158 ,  A61M2005/1583 ,  A61M2005/3223 ,  A61M2005/3224 ,  A61M5/322 ,  A61M5/3232 ,  A61M5/3257

    摘要： A trocar and catheter assembly for automatically disarming the trocar after placement of the catheter into a patient's blood vessel includes a spring urging retraction of the trocar and a releasable retainer mechanism for maintaining the trocar in an extended position during insertion of the catheter into the blood vessel. In one embodiment, the catheter is removably mounted to a handle which defines an internal passage. Disengaging the handle from the catheter after placement of the catheter into the blood vessel actuates the releasable retainer mechanism for allowing the trocar to be drawn into the handle passage under the influence of a spring, to enclose the sharpened end of the trocar after use. In another embodiment, the insertion device is in the form of a pair of wings which are movable between a closed position and an open position. The wings are in their closed position and grasped by the user when inserting the catheter into the blood vessel, and are thereafter moved to their open position. Movement of the wings to their open position actuates the releasable retainer mechanism, and the trocar is then drawn rearwardly so that its sharpened end is drawn into the catheter passage under the influence of the spring.

    摘要翻译： 将导管放置在病人血管中之后，用于自动解除套管针的套管针和导管组件包括：推动套针针回收的弹簧和用于在将导管插入血管内时将套针保持在延伸位置的可释放保持器机构 。 在一个实施例中，导管可移除地安装到限定内部通道的手柄。 将导管放入血管后，从导管上脱下手柄可以启动可释放的保持架机构，以使套管针在弹簧的影响下被拉入手柄通道，以在使用后封闭套管针的尖端。 在另一个实施例中，插入装置是一对翼的形式，它们可在关闭位置和打开位置之间移动。 当将导管插入血管时，翅膀处于关闭位置并被使用者抓住，然后移动到其打开位置。 将机翼移动到其打开位置致动可释放的保持器机构，然后套管针向后拉，使得其尖锐的端部在弹簧的影响下被拉入导管通道。

    Method of restoring the incretin effect
    8.
    发明授权
    Method of restoring the incretin effect 有权
    恢复肠降血糖素作用的方法

    公开(公告)号：US07893080B2

    公开(公告)日：2011-02-22

    申请号：US11876279

    申请日：2007-10-22

    申请人： Anton H. Clemens

    发明人： Anton H. Clemens

    IPC分类号： A61K31/44

    CPC分类号： A61K31/485 ,  A61K31/437 ,  A61K31/4748 ,  A61K38/45 ,  A61K45/06 ,  Y10S514/866

    摘要： The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective κ-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof.

    摘要翻译： 本发明涉及治疗代谢综合征，2型糖尿病，致动脉粥样化血脂异常和/或肥胖症的方法。 本发明还涉及恢复肠降血糖素作用，恢复胰高血糖素水平的生理控制，恢复第一阶段胰岛素分泌和恢复生理葡萄糖依赖性胰岛素分泌的方法。 本发明的方法包括向有需要的受试者施用选择性和受体拮抗剂，例如胍基化的纳曲酮（GNTI）或其药学上可接受的衍生物。

    Method of treating the syndrome of coronary heart disease risk factors in humans
    10.
    发明授权
    Method of treating the syndrome of coronary heart disease risk factors in humans 失效
    治疗冠心病危险因素综合征的方法

    公开(公告)号：US5878750A

    公开(公告)日：1999-03-09

    申请号：US937996

    申请日：1997-09-26

    申请人： Anton H. Clemens

    发明人： Anton H. Clemens

    IPC分类号： A61K31/00 ,  A61K31/198 ,  A61K31/485 ,  A61P9/10 ,  A61B19/00

    CPC分类号： A61K31/485 ,  A61K31/00 ,  A61K31/198

    摘要： A method of treatment of humans suffering from the Coronary Heart Disease Risk Factor (CHDRF) Syndrome which comprises administering, by a pharmaceutically effective mode, a drug composition selected from the group consisting of opiate antagonists or anti-opioids, and drugs which substantially equally reduce the amounts of catecholamines bound to all catecholamine binding sites, is disclosed.

    摘要翻译： 一种治疗患有冠心病危险因素（CHDRF）综合征的人的方法，其包括以药学上有效的方式施用选自阿片剂拮抗剂或抗阿片样物质的药物组合物，以及基本上同样减少的药物 公开了与所有儿茶酚胺结合位点结合的儿茶酚胺的量。